Searched for
DRL SHARES
Reddy Pharma loses 'name' in Delhi HC rulingThe Delhi High Court has ruled against Reddy Pharmaceuticals. The court upheld a decision to remove 'Reddy' from the company's name. Reddy ...- Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27Dr Reddy's Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US business press...
- Should you buy the dip? Strategist Anand James shares his weekly stock strategyMarket expert Anand James suggests caution following recent volatility. He notes the Nifty needs to break above 24,140 for a confirmed upsw...
- Market Outlook: Rupak De’s top 3 trading stock picks for the week aheadGeopolitical tensions, rising crude oil, and a weakening rupee are fueling market volatility, according to Rupak De of LKP Securities. He n...
- Dr. Reddy’s shares rise over 1% on strategic collaboration with Alvotech for Keytruda BiosimilarDr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of Keytruda (pembroli...
- Dr. Reddy’s Laboratories shares in focus on denial of workforce reductionDr. Reddy’s Laboratories shares: In a regulatory filing, the pharmaceutical giant addressed a Business Standard article dated April 13, whi...
- Dr Reddy's shares rally 4% as Nuvama upgrades rating to buyDr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the impact of Re...
- Dr Reddy's tumbles 7% post Q4 results! Here's what brokerages recommendDr Reddy's Laboratories reported an 890% YoY surge in March quarter profit at Rs 960.1 crore but shares tumbled nearly 7% to Rs 4,545 in Th...
- Dr Reddy's Labs Q4 Results: Consolidated profit tanks 76% YoY to Rs 88 croreThe profit figure was sharply lower compared with an ET Now analysts’ poll projection of Rs 560 crore.
- DRL Q3 Results Preview: Profit may grow 25% YoY; margin likely to fallEdelweiss sess profit rising 26.5 per cent YoY to Rs 780 crore. It sees sales rising 12.2 per cent YoY to Rs 5,531 crore. The brokerage see...
- Dr Reddy’s Q2 results: Consolidated PAT rises 30% YoY, beats estimateThe drugmaker reported an 18 per cent on-year rise in consolidated revenues to Rs. 5,763 crore for the reported quarter, which also beat St...
- Neutral on Dr. Reddy's Laboratories, target price Rs 5200: Motilal OswalDr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 80574.04 Crore) operating i...
- Dr Reddy's lines up Rs 1,000 crore capex for current fiscal yearThe Hyderabad based firm invested about Rs 1,000 crore in the 2020-21 fiscal year.
- Dr Reddy’s Labs climbs 4% on sale of API unitDRL did not disclose the deal amount.
- Dr Reddy’s Laboratories gains 3% on receiving EIR for Srikakulam plantThe pharma major last month reported nearly eight-fold jump in consolidated profit after tax to Rs 456.1 crore for the first quarter of 201...
- DRL takes a hit of 10% on US court orderIndivior sees a $25 million dent on its revenues due to the product of Dr Reddy's.
- Dr Reddy's launches Nexium generic in US marketDrug major Dr Reddy's Laboratories (DRL) has launched the generic version of Astrazeneca's Nexium, used to treat acid reflux, in the US mar...
- Dr Reddy's Laboratories acquires 93% shares of OctoPlusDr Reddy's Laboratories has so far managed to get nearly 93% shares of Netherlands-based speciality pharmaceutical company OctoPlus NV.
- Dr Reddy's looks at settling Sanofi dispute out of courtPharma major Dr Reddy’s Laboratories (DRL) is contemplating an out-of-court settlement with the French company Sanofi-Aventis for anti-alle...
- DRL expects verdict in Aciphex case by May 15As the patent clash between Dr Reddy's Labs (DRL) and Japanese pharma firm Eisai for the control over $1.3-billion anti-ulcer drug Aciphex ...
Load More
